Rhythm Pharmaceuticals has filed for an initial public offering with the goal of securing as much as $86 million. The Boston-based biotech firm plans to use some of the money, along with its current cash offerings, to support the development and production of its diabetic gastroparesis drug candidate relamorelin and experimental Prader-Willi Syndrome treatment RM-493.

Related Summaries